{
    "nct_id": "NCT04116073",
    "official_title": "A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer",
    "inclusion_criteria": "* Age ≥18 years.\n* Have histologically or cytologically - proven adenosquamous carcinoma of the pancreas or ampulla.\n* Has unresectable or metastatic measurable disease.\n* Has received (or been intolerant to or ineligible for) at least 1 prior line of cytotoxic chemotherapy and received no more than 2 prior systemic treatments.\n* Presence of at least one lesion with measurable disease.\n* Accept to have a tumor biopsy of an accessible lesion at baseline and on treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* If HIV-positive, then all of the following criteria must also be met: cluster of differentiation (CD) 4+ count ≥ 350/μL, undetectable viral load, and receiving highly active antiretroviral therapy.\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\n* Men must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria\n\n* Known history or evidence of brain metastases.\n* Has had chemotherapy, radiation, or biological cancer therapy within 14 days prior to the first dose of study drug.\n* Has received an investigational agent or used an investigational device within 28 days of the first dose of study drug.\n* Expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Has had major surgery within 28 days of dosing of investigational agent, excluding minor procedures.\n* Has received a live vaccine within 28 days prior to the first dose of study drug.\n* Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, anti-OX40 and LAG-3 antibodies)\n* Have used any systemic steroids within 14 days of study treatment.\n* Hypersensitivity reaction to any monoclonal antibody.\n* Evidence of clinical or radiographic ascites.\n* Have clinically significant and/or malignant pleural effusion.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* History of autoimmune disease requiring systemic immunosuppression within the last 2 years.\n* Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoeitic stem cell transplant will be excluded.\n* All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to a grade 1 or baseline before administration of study drug.\n* Infection with Hepatitis A, B or C.\n* Patient has a pulse oximetry of <92% on room air.\n* Patient is on supplemental home oxygen.\n* Has an unhealed surgical wound or ulcer, or a bone fracture considered non-healing.\n* Patient has clinically significant heart disease.\n* Patient is, at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or other substance abuse.\n* Unwilling or unable to follow the study schedule for any reason.\n* Patient has history of non-infectious pneumonitis.\n* Serum albumin level less than 2.8 g/dL.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}